Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis

Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis

Abstract Background Myelofibrosis (MF) is a life-shortening complication of myeloproliferative neoplasms associated with ineffective hematopoiesis, splenomegaly, and progressive bone marrow (BM) fibrosis. The oral Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib has been shown to improve splenomegaly...

Full description

Bibliographic Details
Main Authors: Hans Michael Kvasnicka, Jürgen Thiele, Carlos E. Bueso-Ramos, William Sun, Jorge Cortes, Hagop M. Kantarjian, Srdan Verstovsek
Format: Article
Language:English
Published: BMC 2018-03-01
Series:Journal of Hematology & Oncology
Subjects:
Bone marrow fibrosis
Myelofibrosis
Ruxolitinib
Hydroxyurea
Online Access:http://link.springer.com/article/10.1186/s13045-018-0585-5

Similar Items

Similar Items